117 completed, 12 unknown, 7 terminated, 6 withdrawn. 48 Phase 4, 39 Phase 3, 16 Phase 2, 13 Not applicable, 11 Phase 1.
Follow Fluticasone-Salmeterol Drug Combination: new trials by email Literature Review of Fluticasone-Salmeterol Drug Combination trials Research Report on Fluticasone-Salmeterol Drug Combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149 - Asthma | Phase 3 | Recruiting | Novartis Pharmaceuticals | 188 | 2026-08-04 | 2026-10-15 |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo - Asthma | Phase 2 | Active not recruiting | Sanofi | 556 | 2024-11-07 | 2026-09-22 |
| Advair HFA in Healthy and HAPE Predisposed Subjects Advair HFA, Placebo - Altitude Edema | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 60 | 2023-12-12 | 2025-09-22 |
| Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK, Placebo - Asthma | Phase 3 | Unknown | Respirent Pharmaceuticals Co Ltd. | 451 | 2023-01-30 | 2023-03-01 |
| Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma Salmeterol Xinafoate, Salmeterol Fluticasone - Asthma | Phase 4 | Unknown | Imperial College London | 24 | 2021-07-23 | 2023-04-25 |
| Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation Seretide, Placebo - Stem Cell Transplant Complications, Respiratory Disease | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 35 | 2021-05-21 | 2025-09-16 |
| A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication - Asthma | Phase 4 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 427 | 2021-02-16 | 2023-03-14 |
| Replication of the INSPIRE Trial in Healthcare Claims Data Tiotropium, salmeterol-fluticasone - Chronic Obstructive Pulmonary Disease | Completed | Brigham and Women's Hospital | 98278 | 2020-09-22 | 2023-07-27 | |
| Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma Fluticasone Propionate and Salmeterol Inhalation Powder, Placebo Inhalation Powder - Asthma | Phase 3 | Completed | Actavis Inc. | 999 | 2018-12-03 | 2021-09-24 |
| A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg, ADVAIR DISKUS - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2018-11-20 | 2018-12-28 |
| A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK, Placebo - Asthma | Phase 3 | Completed | Respirent Pharmaceuticals Co Ltd. | 451 | 2018-10-02 | 2020-07-07 |
| A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50 Test Product, Reference Product, Placebo - Asthma | Phase 3 | Unknown | Amneal Ireland Limited | 1204 | 2018-10-01 | 2018-06-20 |
| Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD Salbutamol (Ventolin®), Tiotropium Bromide (Spiriva®), Salmeterol / fluticasone (Seretide®) - Pulmonary Disease, Chronic Obstructive | Phase 3 | Unknown | Henan University of Traditional Chinese Medicine | 240 | 2018-06-20 | 2018-11-19 |
| Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. CMAB007, Symbicort, Seretide - Asthma, Allergic | Phase 3 | Completed | Shanghai Biomabs Pharmaceutical Co., Ltd. | 393 | 2018-05-09 | 2021-10-11 |
| Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg) Fluticasone propionate/salmeterol, Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder, Placebo - Asthma | Not applicable | Completed | West-Ward Pharmaceutical | 1556 | 2018-04-26 | 2019-11-29 |
| Personalized Treatment Algorithms for Difficult-to-treat Asthma Cholecalciferol, antihistamine, Azithromycin - Asthma in Children | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 21 | 2018-03-16 | 2021-08-20 |
| Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination - Asthma | Phase 2 | Completed | Sanofi | 296 | 2018-03-12 | 2022-06-14 |
| Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD) Nebulizers, Dry Powder Inhaler, Brovana - COPD, COPD Exacerbation | Phase 4 | Terminated | Wake Forest University Health Sciences | 40 | 2017-10-03 | 2021-06-22 |
| Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma GSK3772847, Placebo, Fluticasone propionate/salmeterol - Asthma | Phase 2 | Completed | GlaxoSmithKline | 165 | 2017-09-14 | 2020-03-02 |
| Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI) salmeterol-fluticasone - Asthma | Phase 1 | Completed | Orion Corporation, Orion Pharma | 64 | 2017-08-16 | 2018-04-06 |
Showing 20 of 147. Sign in to see all of them.
Asthma (85) · Pulmonary Disease, Chronic Obstructive (48) · Lymphoma, Follicular (4) · Inflammation (3) · Motor Activity (3) · Respiration Disorders (3) · Asthma, Exercise-Induced (2) · Bronchial Spasm (2) · Depression (2) · Hypersensitivity (2) · Lung Diseases (2) · Respiratory Hypersensitivity (2) · Rhinitis, Allergic (2) · Altitude Sickness (1) · Anxiety Disorders (1)
GlaxoSmithKline (48) · Novartis Pharmaceuticals (8) · Teva Branded Pharmaceutical Products R&D, Inc. (7) · AstraZeneca (4) · Henan University of Traditional Chinese Medicine (4) · Johns Hopkins University (3) · Respirent Pharmaceuticals Co Ltd. (3) · Sanofi (3) · Actavis Inc. (2) · Chiesi Farmaceutici S.p.A. (2) · Gelb, Arthur F., M.D. (2) · Milton S. Hershey Medical Center (2) · National Jewish Health (2) · Organon and Co (2) · Orion Corporation, Orion Pharma (2)
United States (58) · Germany (23) · United Kingdom (18) · Canada (16) · Poland (15) · Spain (14) · Hungary (13) · Russia (13) · China (12) · Argentina (11) · Belgium (10) · France (10) · Italy (10) · Lithuania (10) · Czechia (9)
Arthur F Gelb, MD (3) · Catherine Bonuccelli (3) · Adam Wanner, MD (2) · Don Sin, MD (2) · William Busse, MD (2) · Alberto Papi, MD (1) · Alyn H Morice, Professor (1) · Arun Nair (1) · Athanasios Konstantinidis, Ass.Professor (1) · Beverley Patterson, PhD (1)
PMID 36472162, PMID 20167147, PMID 20705799, PMID 22560478, PMID 23932460, PMID 24290280, PMID 25950858, PMID 26343939, PMID 26717511, PMID 34452934, PMID 37347518, PMID 15741443, PMID 17629923, PMID 18310480, PMID 19237390, PMID 19820080, PMID 19910613, PMID 20170333, PMID 20197425, PMID 20627920, PMID 20874458, PMID 21240480, PMID 21636667, PMID 21778259, PMID 21980058, PMID 22152089, PMID 22221427, PMID 22568828, PMID 22749044, PMID 23524015, PMID 23537051, PMID 24168756, PMID 24321804, PMID 24387157, PMID 24621109, PMID 24885672, PMID 24913725, PMID 25044280, PMID 25248764, PMID 26006754, PMID 26082625, PMID 26286141, PMID 26289742, PMID 26752024, PMID 26949137, PMID 27216137, PMID 27492833, PMID 27579634, PMID 27715335, PMID 27849125
2015 (4), 2017 (2), 2008 (1), 2009 (1), 2016 (1), 2019 (1), R01HL114899 (1), U01OH010404 (1), U10HL064287 (1), U10HL064288 (1), U10HL064295 (1), U10HL064305 (1), U10HL064307 (1), U10HL064313 (1), U10HL098115 (1)